Captain - Stay the course!, page-4

Sounds exactly like the response I got last week from investor relations Full steam ahead Captain Mozz

which was
Paradigm’s management are constantly assessing a range of indications that iPPS may have a benefit.


Before Paradigm announces to the market the use of PPS in treating the various potential indications, Paradigm’s CMO and CSO have developed a strategic approach to the question re the use of PPS:.


1.It is important to generate a detailed scientific rationale to the use of PPS for the indication. This comprises the use of peer-reviewed data on the effects of PPS in the pathogenesis of the disease;

2.Search for the most translatable preclinical model;

3.Conduct proof of concept study of PPS in the preclinical model. In particular we need to establish the entry point of treatment ie is it in the acute phase or chronic phase.


A commercial decision on Paradigm’s investment in any particular study must also be made to make sure we have a path for a return on any investment that is made.